Mh. Kollef et al., A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients, CHEST, 116(5), 1999, pp. 1339-1346
Citations number
33
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Study objectives: To determine whether the application of continuous aspira
tion of subglottic secretions (CASS) is associated with a decreased inciden
ce of ventilator-associated pneumonia (VAP),
Design: Prospective clinical trial.
Setting: Cardiothoracic ICU (CTICU) of Barnes-Jewish Hospital, St. Louis, a
university-affiliated teaching hospital.
Patients: Three hundred forty-three patients undergoing cardiac surgery and
requiring mechanical ventilation in the CTICU.
Interventions: Patients were assigned to receive either CASS, using a speci
ally designed endotracheal tube (Hi-Lo Evac; Mallinckrodt Inc; Athlone, Ire
land), or routine postoperative medical care without CASS,
Results: One hundred sixty patients were assigned to receive CASS, and 183
were assigned to receive routine postoperative medical care without CASS, T
he two groups were similar at the time of randomization with regard to demo
graphic characteristics, surgical procedures performed, and severity of ill
ness. Risk factors for the development of VAP were also similar during the
study period for both treatment groups. VAP was seen in 8 patients (5.0%) r
eceiving CASS and in 15 patients (8.2%) receiving routine postoperative med
ical care without CASS (relative risk, 0.61%; 95% confidence interval, 0.27
to 1.40; p = 0.238), Episodes of VAP occurred statistically later among pa
tients receiving CASS ([mean +/- SD] 5.6 +/- 2.3 days) than among patients
who did not receive CASS (2.9 +/- 1.2 days); (p = 0.006). No statistically
significant differences for hospital mortality overall duration of mechanic
al ventilation, lengths of stay in the hospital or CTICU, or acquired organ
system derangements were found between the two treatment groups. No compli
cations related to CASS were observed in the intervention group.
Conclusions: Our findings suggest that CASS can be safely administered to p
atients undergoing cardiac surgery. The occurrence of VAP can be significan
tly delayed among patients undergoing cardiac surgery using this simple-to-
apply technique.